 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
February 14, 2013
Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News - Alnylam, Tekmira Shares Regain Lost Ground Heading into 2013
January 24, 2013 / Gene Silencing News - Alnylam to Sell $125M in Stock
January 17, 2013 / Gene Silencing News - Alnylam, Tekmira End Litigation with $65M Settlement
November 15, 2012 / Gene Silencing News